Figure 2.

siRNA Targeting CDR1as (siCDR1as) Prevents HPASMC Calcification in Hyp

(A) Representative images of ARS staining in Nor and NC, Hyp and NC, and Hyp and siCDR1as groups (B) Immunofluorescent staining of Runx2 in fixed HPASMCs. Scale bar, 50 μm. (C) ALP activity was measured in HPASMCs after siCDR1as. (D) Quantification of calcium content in HPASMCs. The results shown were normalized to the total protein amount. (E) HPASMCs were exposed to Hyp, and the expression of SOX9, MSX2, SM22α, and BMP2 was evaluated by western blot with β-actin as a standard. ∗p < 0.05, ∗∗p < 0.01 versus Nor + NC; #p < 0.05, ##p < 0.01 versus Hyp + NC. All tests were performed at least three times, and the values are presented as the mean ± SEM.